Combination hormonal therapy: a reassessment within advanced prostate cancer

Recent advances in hormonal therapy for advanced prostate cancer.

Hormonal treatment of advanced prostate cancer should be considered for patients who have stages C and D1 disease, a high risk of recurrence after local therapy, or prostate-specific antigen-measured recurrence after local treatment. This approach is dependent on most prostate cancer cells being androgen-dependent, but androgen-independent cells may arise after several years of hormonal therapy...

Contemporary hormonal management of advanced prostate cancer.

The traditional definition of "advanced" prostate cancer includes only patients with widespread osteoblastic or soft-tissue metastases (clinical or pathologic stage T any N any M1; or stage D2). Current evidence indicates that this definition should be broadened. Because many patients with T3 disease or local lymph node metastases progress to distant metastases, the concept of advanced prostate...

Ketoconazole as a secondary hormonal intervention in advanced prostate cancer.

Prostate cancer is the most common nonskin cancer in American men, and androgen-deprivation therapy is the cornerstone of treatment for advanced prostate cancer. Unfortunately, the median duration of response to initial androgen deprivation is limited to 18–24 months. After failing primary therapy, many individuals respond to multiple secondary hormonal interventions, such as ketoconazole. A po...

Hormonal Therapies for Patients with Advanced Prostate Cancer

Prostate cancer (PCa) is the second most common cancer in men, comprising 15% of new cancer cases. While most cases are diagnosed at an early stage and can be managed conservatively or by local treatment alone, up to 30% of patients will receive androgen deprivation therapy (ADT). Indeed, high-risk localised and locally advanced PCa require either surgery or ADT in combination with radiation as...

Gene Therapy in Advanced Prostate Cancer: